NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
STEGLATRO (ertugliflozin) by Merck & Co. is 2 diabetes mellitus: ertugliflozin, a sglt2 inhibitor, and metformin hydrochloride, a member of the biguanide class. First approved in 2017.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STEGLATRO (ertugliflozin) is an oral SGLT2 inhibitor combined with metformin for type 2 diabetes mellitus that works by blocking kidney glucose reabsorption and improving insulin sensitivity. The combination therapy lowers both fasting and postprandial glucose levels through dual mechanisms: renal glucose excretion and improved hepatic/peripheral glucose uptake. It represents a modern approach to glycemic control in patients inadequately controlled on monotherapy.
$0.018BPart D
Peak5.5 years to LOEProduct is at peak commercial maturity with modest Part D utilization; brand team likely sized for stable maintenance rather than growth expansion.
Mechanism of Action
2 diabetes mellitus: ertugliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class. Ertugliflozin SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
Started Jul 2023
34 enrolled
Type 2 Diabetes
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
Started Jul 2023
41 enrolled
Diabetes MellitusDiabetic Kidney DiseaseHypertension
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
Started Jun 2021
Ertugliflozin in Chronic Heart Failure
Started Mar 2021
60 enrolled
Heart Failure
Ertugliflozin for Functional Mitral Regurgitation
Started Nov 2020
128 enrolled
Mitral Valve InsufficiencyLeft Ventricular Systolic Dysfunction
Worked on STEGLATRO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.